Introduction {#s1}
============

Major depressive disorder (MDD) is a common psychiatric disorder associated with high disability, mortality, and socioeconomic cost ([@CIT0039]; [@CIT0027]). Inadequate and delayed response to treatment is a major problem in MDD, and only about 50% of the patients respond adequately to treatment with the most commonly prescribed antidepressant drugs, the selective serotonin reuptake inhibitors (SSRIs) ([@CIT0042]; [@CIT0042]). Even when the antidepressant treatment effectively improves affective symptoms, residual cognitive symptoms may persist ([@CIT0006]) and the degree of cognitive impairment may determine treatment outcome, as for example schizophrenia and bipolar disorder (BPD) ([@CIT0020]; [@CIT0036]; [@CIT0035]). Substantial clinical data support the adjunctive use of low to moderate doses of atypical antipsychotic drugs (APDs) in combination with SSRIs to rapidly enhance the antidepressant effect in treatment-resistant MDD and bipolar depression (see, e.g., [@CIT0038]; [@CIT0011]; [@CIT0053]). Preclinical studies have demonstrated increased outflow of both dopamine and noradrenaline in the medial prefrontal cortex (mPFC) by the combination of olanzapine or quetiapine with the noradrenaline reuptake inhibitor reboxetine or the SSRI fluoxetine ([@CIT0059]; [@CIT0024]; [@CIT0005]), which has been suggested to contribute to the potent antidepressant effect observed with such drug combinations ([@CIT0059]). Asenapine is a novel atypical APD with a multi-receptor binding profile and a structure similar to that of the antidepressant drug mirtazapine. In binding studies, asenapine exhibits higher affinity for 5-HT~2A~, 5-HT~2c~, 5-HT~6~, 5-HT~7~, and α~2~-adrenoceptors than for dopamine D~2~ receptors (D2Rs) ([@CIT0016]), which all may contribute to its clinical efficacy. Moreover, asenapine acts as a partial agonist at 5-HT~1A~receptors (5-HT1AR; [@CIT0018]; [@CIT0016]). The receptor binding profile of asenapine differs slightly from that of other APDs, for example, risperidone (which has weaker 5-HT~1A~ and 5-HT~6~ affinity), olanzapine (weaker 5-HT~1A~ and α~2~ affinity), quetiapine (weaker 5-HT~2C~ and 5-HT~6~), and clozapine (stronger M~1-4~ and α~2C~ affinity; [@CIT0016]).

In clinical studies, asenapine has been found to be effective in schizophrenia and bipolar mania as well as to reduce depressive symptoms in BPD and schizophrenia ([@CIT0037]; [@CIT0026]; [@CIT0052]). Asenapine is generally well tolerated with low propensity to induce extrapyramidal or anticholinergic side effects, substantial weight gain, or change in metabolic parameters ([@CIT0026]).

Preclinical studies have shown that asenapine increases dopamine, noradrenaline, and serotonin output in the mPFC, partly via activity at 5-HT~2A~ receptors (5-HT2ARs) and α~2~-adrenoceptors ([@CIT0015] [@CIT0016] [@CIT0017]; [@CIT0021]), which may indicate an inherent antidepressant activity in addition to the amelioration of positive and negative symptoms in schizophrenia as well as cognitive impairment. Furthermore, asenapine has also been shown to facilitate *N*-methyl-[d]{.smallcaps}-aspartate (NMDA)-induced currents in pyramidal cells of the mPFC via dopamine D1 receptor (D1R)-mediated mechanisms ([@CIT0024]). The functional relevance of this mechanism was shown in behavioral studies where asenapine via D1Rs was found to reverse cognitive impairment induced by NMDA receptor (NMDAR) antagonists ([@CIT0047]).

Because the receptor binding profile of asenapine as well as its clinical profile indicates that it may be effective in augmenting antidepressant drugs in depression, we investigated here whether adjunctive treatment with asenapine, at subeffective doses not yielding full antipsychotic-like activity ([@CIT0015]), may enhance the effect of the SSRI escitalopram on extracellular levels of dopamine, noradrenaline, and serotonin in the mPFC as well as dopamine in nucleus accumbens (NAc) using in vivo microdialysis in awake and freely moving animals. Moreover, the effects of asenapine and escitalopram, given alone and in combination, on NMDAR- and AMPA receptor (AMPAR)-mediated glutamatergic transmission as well as on electrically evoked excitatory postsynaptic potentials (EPSPs) were studied using intracellular electrophysiological recordings in vitro in pyramidal cells of the mPFC.

Materials and methods {#s2}
=====================

Animals {#s3}
-------

Male Wistar rats (Charles River Laboratories, Germany) weighing \~250g upon arrival were used for the microdialysis experiments. For the in vitro electrophysiological experiments, male Sprague Dawley rats with a mean weight of 190.1±7.8g were used. The animals were housed under standard laboratory conditions (21.0±0.4°C; relative humidity of 55--65%). Food (R34, Ewos, Södertälje, Sweden) and tap water were available ad libitum. The animals were kept on a 12/12 h light/dark cycle (lights on at 6:00 [am]{.smallcaps}) and were acclimatized for at least 5 days before the experiments. Experiments were performed between 8:00 [am]{.smallcaps} and 6:00 [pm]{.smallcaps}. All experiments were approved by the local Animal Ethics Committee, Stockholm North, and the Karolinska Institutet, Sweden.

In Vivo Microdialysis {#s4}
---------------------

Rats were anesthetized with Hypnorm (0.315mg/mL fentanyl citrate and 10mg/mL fluanisone; Janssen-Cilag, UK) and Dormicum (5mg/mL midazolam; Roche AB, Sweden) diluted in distilled water (1:1:2; 5mL/kg, intraperitoneal injection) and sterotactically implanted with concentric dialysis probes in the mPFC (at a 12° angle) or NAc (anteroposterior +2.5, +1.6; mediolateral −1.4, −1.4; dorsoventral −6.0, −8.2), respectively, relative to bregma and dural surface (in mm) ([@CIT0040]). Dialysis probes were manufactured in-house with a semipermeable membrane (Filtral AN69, Hospal Industrie, France) with an active surface length of 5.5mm (mPFC) or 2mm (NAc). Dialysis experiments were conducted approximately 48 hours after surgery in awake and freely moving rats. The dialysis probe was perfused with a physiological perfusion solution (in mM: 147 NaCl, 3.0 KCl, 1.3 CaCl~2~, 1.0 MgCl~2~, 1.0 Na~2~HPO~4~, and 0.2 NaH~2~PO~4~, pH 7.4) at a rate of 2.5 μL/min. Dialysate samples were collected during 30-minute (mPFC) or 15-minute (NAc) intervals and automatically injected into a high performance liquid chromatography system and quantified by electrochemical detection (ESA Bioscience) with a detection limit of approximately 0.08 nM. The injector (Valco Instruments) was directed by Totalchrom WS 6.3 software (Perkin Elmer). Separation of neurotransmitters and metabolites was achieved by reversed-phase liquid chromatography on a C-18 column (Kinetex 150×4.6mm, 2.6 µm, Phenomenex). The mobile phase used for separation of catecholamines (NAc or mPFC) or serotonin alone (mPFC) consisted of a 55-mM sodium acetate buffer, pH 4.0, with 12% or 18% methanol and 0.55 or 0.81mM octanesulfonic acid, respectively. Samples were quantified by sequential oxidation and reduction in a high sensitive analytical cell (model 5011; ESA Bioscience) that was controlled by a potentiostat (Coulochem II model 5200; ESA Bioscience) with applied potentials of 400 and −200 mV for detection of metabolites and monoamines, respectively. Injection of drug was performed when a stable outflow (\<10% variation) of the neurotransmitters was established. Baseline (100%) was calculated as the average of the last 2 (mPFC) or 4 (NAc) preinjection values. At the end of the experiment, tetrodotoxin (3 µM) was infused into the probe to further verify peak identification. Placement of the probes was verified under microscope in Nissl stained sections.

Preparation of Brain Slices and Electrophysiological Experiments in Vitro {#s5}
-------------------------------------------------------------------------

The preparation of brain slices and electrophysiological experiments in vitro were performed as previously described ([@CIT0025]). In short, rats were anesthetized (halothane; Astra AB, Sweden), and the brain was quickly removed and cooled in ice-cold Ringer's solution (in mM: 126 NaCl, 18 NaHCO~3~, 10 [d]{.smallcaps}-glucose, 2.5 KCl, 2.4 CaCl~2~, 1.3 MgCl~2~, 1.2 NaH~2~PO~4~, pH 7.4) aerated with 95% O~2~:5% CO~2~. The brains were sectioned coronally to 450-µm slices using a Vibroslice (Campden model MA752, World Precision Instruments). The slices were kept in aerated Ringer's solution at room temperature for \>1 hour to allow for recovery. A slice containing the mPFC was fixed in the recording chamber between 2 nylon nets and was continually perfused with aerated Ringer's solution (30°C; flow rate of 1--2mL/min). Recording electrodes were pulled from borosilicate glass capillaries (i.d. 0.58mm; Clark Electromedical Instruments) and filled with 2M potassium acetate (resistance: 55--140 MΩ) and used for recording with an Axoclamp 2B amplifier (Molecular Devices). Penetration of layer V or VI cells with sharp electrodes was performed blindly. Single electrode voltage-clamp (holding potential: -- 60 mV) was performed in the discontinuous mode (sampling rate of 5--6.2kHz). Voltage-clamp recordings were acquired using digital/analogue sampling and acquisition software (Clampex version 9.2 Molecular Devices). Tetrodotoxin (0.5 µM, to block action potentials), bicuculline (5 µM, to block the GABA~A~ receptor), and glycine (1 µM, to enhance the NMDA-induced currents) were routinely included in the Ringer's solution during the recordings. All drugs, including AMPA (2.5 µM) and NMDA (10--15 µM), were diluted in Ringer's solution and applied via bath perfusion. NMDA and AMPA applications were performed at 5 and 30 minutes of drug treatment. In experiments in which the dopamine D1/5 receptor antagonist SCH23390 was included, the slice was pretreated with SCH23390 (1 µM) for 5 minutes before the administration of asenapine and escitalopram commenced. To calculate the effects of the drugs or drug combinations on the prefrontal glutamatergic transmission, the recorded amplitude of AMPA- or NMDA-induced current after administration of a drug or a drug combination was divided by the amplitude of the control AMPA- or NMDA-induced current.

To elicit EPSPs in pyramidal cells, a stimulation electrode consisting of 2 stainless steel tips was placed medially in the forceps minor (white matter) close to the recording electrode, and a square pulse (0.3-millisecond duration, 11--31V) was passed between the tips of the stimulation electrode. The evoked change in membrane potential (ie, the EPSP) of a layer V or VI pyramidal cell of the mPFC was then recorded in the current clamp mode. To evaluate the effect of the drugs or drug combination on the electrically evoked EPSPs, a submaximal potential was chosen, and the evoked response was recorded before and after 5, 15, 25, and 35 minutes of drug application. Bicuculline (2 µM) was routinely included in the perfusion solution (Ringer's) to inhibit GABA~A~ receptor-mediated inhibitory postsynaptic potentials. The effect of the drugs and the drug combination on electrically evoked EPSPs was evaluated both qualitatively for their ability to facilitate the induction of action potentials as well as their effect on the total area of the EPSP.

Drugs {#s6}
-----

Asenapine was generously obtained from Schering-Plough, UK and Merck Sharp & Dohme Corp (MSD) and escitalopram was generously obtained from Lundbeck A/S, Denmark. Tetrodotoxin, bicuculline, and (RS)-AMPA were purchased from Ascent Scientific, Bristol, UK, and glycine and NMDA were purchased from Sigma-Aldrich, St. Louis, MO. For the in vivo microdialysis experiments, asenapine and escitalopram were dissolved in physiological saline (0.9% NaCl) and subcutaneously (s.c.) injected at a volume of 1.0mL/kg. For the in vitro electrophysiological experiments, stock solutions of asenapine (dissolved in purified water) and escitalopram (dissolved in dimethyl sulfoxine and diluted to stock concentration with purified water) were prepared and then diluted in Ringer's solution to reach the final drug concentration.

Statistics {#s7}
----------

The effect of the drug treatments on the mean transmitter output during intervals of 60 to 240min for mPFC and 45 to 240min for NAc was statistically analyzed using 1-way ANOVA, followed by planned comparisons of Least Squares means. In vitro electrophysiological data of the NMDA and AMPA applications were analyzed using paired Student's *t* test and, for multiple comparisons, 1-way ANOVA followed by the Newman-Keul's multiple comparison test. The drug effect on the total EPSP area was analyzed using repeated-measures 2-way ANOVA followed by Fisher's Least Significant Difference test. Statistical evaluation of microdialysis data and the EPSP area was performed using Statistica version 10 software (StatSoft, Tulsa, OK), and the effect on NMDA- and AMPA-induced currents was analyzed using Prism 5.02 (Graphpad Software Inc.). In all statistical assessments, *P*\<.05 was considered significant.

Results {#s8}
=======

Asenapine 0.05mg/kg Potentiates the Effect of Escitalopram on Dopamine Output in the mPFC and NAc {#s9}
-------------------------------------------------------------------------------------------------

The basal dopamine, noradrenaline, and serotonin output in the mPFC were 0.54±0.06 (mean±SEM, n=24), 1.17±0.14 (n=23), and 0.56±0.05 (n=26) fmol/min, respectively, and for dopamine in NAc 3.23±0.33 (n=25) fmol/min. There were no statistically significant differences between mean baseline concentrations of each neurotransmitter between the different treatment groups.

To assess the effects of the drugs alone and in combination, we analyzed the mean transmitter output after the second injection, that is, 60 to 240 minutes for mPFC and 45 to 240 minutes for NAc. Analysis of the dopamine output showed an overall effect in the mPFC (1-way ANOVA; F~3,20~=16.32, *P*\<.001) ([Figure 1b](#F1){ref-type="fig"}). Asenapine, alone and in combination with escitalopram, increased dopamine output in the mPFC compared with control (*P*\<.01-.001), whereas escitalopram had no effect. The combination of escitalopram and asenapine significantly increased dopamine output compared with either drug alone (*P*\<.05-.001).

![The effects of escitalopram (5mg/kg, subcutaneously \[s.c.\]), asenapine (0.05mg/kg, s.c.) alone, and the combination of escitalopram and asenapine on dopamine (a-b), noradrenaline (c-d), and serotonin (e-f) output in the medial prefrontal cortex (mPFC) and dopamine (g-h) output in nucleus accumbens (NAc). Left panels show the effects over time, whereas right panels show the effects calculated as mean transmitter output during 60 to 240 minutes for the mPFC data and 45 to 240 minutes for NAc data, ie, after the second injection. Arrows indicate injections of escitalopram/ saline and asenapine/saline, respectively. The dotted line represents baseline (100%). The results are presented as mean ± SEM. The number in each bar indicates group size. \**P*\<.05, \*\**P*\<.01, \*\*\* *P*\<.001 vs. control, ie, saline + saline. \#*P*\<.05, \#\#\#*P*\<.001 as indicated in the figures.](ijnppy_pyu068_f0001){#F1}

Analysis of noradrenaline output in the mPFC showed an overall effect (F~3,19~=4.35, *P*\<.05) ([Figure 1d](#F1){ref-type="fig"}). Asenapine treatment enhanced noradrenaline outflow in the mPFC compared with control (*P*\<.05); this effect was, however, not further enhanced when asenapine was combined with escitalopram. Escitalopram treatment alone did not affect noradrenaline outflow.

Analysis of serotonin output in the mPFC showed an overall effect (F~3,22~=16.08, *P*\<.001) ([Figure 1f](#F1){ref-type="fig"}). Escitalopram given alone and in combination with asenapine significantly increased serotonin output in the mPFC compared with control (*P*\<.001). However, asenapine treatment alone did not affect serotonin outflow, nor did addition of asenapine further enhance the effect of escitalopram on serotonin output.

Analysis of dopamine output in NAc showed an overall effect (F~3,21~=6.27, *P*\<.001) ([Figure 1h](#F1){ref-type="fig"}). Escitalopram, asenapine, and the combination of escitalopram and asenapine significantly increased dopamine output compared with control (*P*\<.05- *P*\<.001). However, there was no further enhancement by the combination of escitalopram and asenapine compared with either drug alone. The effect of escitalopram (5mg/kg) on accumbal dopamine output has previously been reported ([@CIT0017]); however, it is now analyzed within the same time interval as our novel data, that is, between 45 and 240 minutes.

Asenapine 0.1mg/kg Potentiates the Effects of Escitalopram on Serotonin and Noradrenaline Output in the mPFC {#s10}
------------------------------------------------------------------------------------------------------------

The effect of a higher dose of asenapine (0.1mg/kg) alone and in combination with escitalopram (5mg/kg) was also investigated. In this group, the mean±SEM basal outflow of dopamine, noradrenaline, and serotonin in mPFC were 0.47±0.05 (n=27), 0.91±0.10 (n=26), and 0.39±0.03 (n=28) fmol/min, respectively, and for dopamine in NAc 2.95±0.31 (n=29) fmol/min. There were no statistically significant differences in the mean baseline concentrations of each neurotransmitter between different treatment groups.

The effects of asenapine (0.1mg/kg) on dopamine and noradrenaline output have also previously been reported ([@CIT0015] [@CIT0016]); however, the data are now analyzed within the same time interval as our novel data.

Analysis of the dopamine output showed an overall effect in the mPFC (60--240 minutes; 1-way ANOVA; F~3,23~=22.15, *P*\<.001) ([Figure 2b](#F2){ref-type="fig"}). Asenapine treatment (0.1mg/kg) significantly increased dopamine output compared with control (*P*\<.001), whereas escitalopram administration did not. In contrast with the effect of the lower dose of asenapine (0.05mg/kg), the effect of addition of the higher dose of asenapine to escitalopram on dopamine output did not reach statistical significance.

![The effects of escitalopram (5mg/kg, subcutaneously \[s.c.\]), asenapine (0.1mg/kg, s.c.) alone, and the combination of escitalopram and asenapine dopamine (a-b), noradrenaline (c-d), and serotonin (e-f) output in the medial prefrontal cortex (mPFC) and dopamine output in nucleus accumbens (NAc) (g-h). Left panels show the effects over time, whereas right panels show the effects calculated as mean transmitter output during 60 to 240 minutes for the mPFC and 45 to 240 minutes for NAc, ie, after the second injection. Arrows indicate injections of escitalopram/saline and asenapine/saline, respectively. The dotted line represents baseline (100%). The results are presented as mean ± SEM. The number in each bar indicates group size. \**P*\<.05, \*\**P*\<.01, \*\*\**P*\<.001 vs. control, ie, saline + saline. \#\#*P*\<.01, \#\#\#*P*\<.001 as indicated in the figures. Note: The data for saline+saline and escitalopram (5mg/kg) are the same as in Figure 1.](ijnppy_pyu068_f0002){#F2}

Analysis of noradrenaline output showed an overall effect in the mPFC (F~3,22~=20.88, *P*\<.001) ([Figure 2d](#F2){ref-type="fig"}). Although there was no effect of either asenapine or escitalopram on noradrenaline output when given separately, the combination of escitalopram and asenapine significantly increased noradrenaline outflow when compared either with vehicle or with each drug given alone (*P*\<.001).

Analysis of serotonin output showed an overall effect in the mPFC (F~3,24~=24.73, *P*\<.001) ([Figure 2f](#F2){ref-type="fig"}). Escitalopram administered alone increased the cortical serotonin concentrations, an effect that was further augmented by adjunctive asenapine, and the combined effect was significantly higher than the effect of either drug given alone (*P*\<.01-.001).

In NAc, the overall effect for dopamine output was statistically significant (45--240 minutes; F~3,25~=11.72; *P*\<.001) ([Figure 2h](#F2){ref-type="fig"}). Compared with control, escitalopram, asenapine, and the combination of escitalopram and asenapine all significantly increased dopamine output (*P*\<.05-0.001). Addition of asenapine significantly increased the escitalopram-induced dopamine outflow (*P*\<.01), but the effect was not larger than that of asenapine given alone.

Electrophysiological Characterizations of Pyramidal Cells of the mPFC {#s11}
---------------------------------------------------------------------

The electrophysiological criteria for distinguishing presumed pyramidal from nonpyramidal cells were previously described ([@CIT0004]). In short, the presumed pyramidal neurons of the mPFC have a relatively long spike duration (1--3 milliseconds at half-maximum spike amplitude) and, in addition, show a pronounced spike frequency adaptation in response to constant-current depolarization pulses. In the present study, the presumed pyramidal cells of layers V and VI of the rat mPFC exhibited a mean membrane potential of −79.8±1 mV (n=60), action potential amplitude of 108.0±2.8 mV (n=60), a spike half width of 4.0±0.2 milliseconds (n=30), and an after-hyperpolarization potential of 4.4±0.4 mV (n=60) in Ringer's solution. These results are similar to previously published results ([@CIT0004]; [@CIT0028]; [@CIT0005]).

Add-on Asenapine to Escitalopram Facilitates NMDA-Induced Currents in Pyramidal Cells of the Rat mPFC via D~1~ Receptor Activation {#s12}
----------------------------------------------------------------------------------------------------------------------------------

Asenapine produces a biphasic concentration response curve with a maximum response at 5nM ([@CIT0015]). Also, escitalopram has been found to potentiate NMDA-induced currents in pyramidal cells of the mPFC at both 5 and 100nM ([@CIT0044]). A combination of submaximal concentrations of asenapine (1nM) and escitalopram (3nM) significantly facilitated the NMDA-induced currents after 30 minutes (182.0±17.5 %, n=5, paired *t* test *P*\<.05) compared with control, as well as each drug given alone (1-way ANOVA \[F~3,17~=8.1, *P*\<.01\], Newman-Keuls multiple comparison test *P*\<.01) ([Figure 3f](#F3){ref-type="fig"}). The facilitating effect of the combination of asenapine and escitalopram was blocked by the addition of the D1R-antagonist SCH23390 (1 µM; 95.3±20.6%, n=4) ([Figure 3f](#F3){ref-type="fig"}).

![Effects on *N*-methyl-[d]{.smallcaps}-aspartate (NMDA)-induced currents in pyramidal cells of the rat medial prefrontal cortex (mPFC). Representative electrophysiological traces showing the effect of NMDA application before (grey trace) and after application (black trace) of 3nM escitalopram (a), 1nM asenapine (b), 3nM escitalopram + 1nM asenapine (c), and 3nM escitalopram + 1nM asenapine + 1 µM SCH23390 (d). The grey and black horizontal bars indicate time of NMDA application for control and test trace, respectively. Data is summarized in bar charts 5 minutes (e) and 30 minutes (f) after drug application. The results are presented in percent as mean ± SEM. \**P*\<.05 vs. control response. \#\#*P*\<.01 as indicated in the figure (n=4--6). The holding potential was −60 mV.](ijnppy_pyu068_f0003){#F3}

Add-on Asenapine to Escitalopram Facilitates AMPA-Induced Currents in Pyramidal Cells of the rat mPFC via D~1~ Receptor Activation {#s13}
----------------------------------------------------------------------------------------------------------------------------------

Neither asenapine nor escitalopram affected the AMPA-induced currents at any concentration tested ([Figure 4a](#F4){ref-type="fig"}-b). However, a combination of low concentrations of asenapine (1nM) and escitalopram (3nM) significantly potentiated AMPA-induced currents at both 5 minutes (173.6±15.9%, n=5, paired *t* test, *P*\<.01) ([Figure 5e](#F5){ref-type="fig"}) and 30 minutes (153.0±7.0%, n=5, *P*\<.05) ([Figure 5f](#F5){ref-type="fig"}). Between-groups comparison showed that the combination of asenapine and escitalopram facilitated the AMPA-induced current at both 5 minutes (1-way ANOVA \[F~3,19~=11.2, *P*\<.001\], Newman-Keuls multiple comparison test, *P*\<.001) ([Figure 5e](#F5){ref-type="fig"}) and 30 minutes (F~3,17~=9.0, *P*\<.01, *P*\<.05-.01) ([Figure 5f](#F5){ref-type="fig"}) compared with either drug given alone. Interestingly, also the potentiating effect of asenapine combined with escitalopram on the AMPA-induced currents was blocked by SCH23390 (1 µM; [Figure 5e](#F5){ref-type="fig"}, 88.0±13.1%, n=4; [Figure 5f](#F5){ref-type="fig"}, 84.3±14.0%, n=4), although SCH23390 (1 µM) treatment did not significantly affect AMPA-induced currents when administered alone (5 minutes, 119.0±23.7%, n=5; 30 minutes, 86.75±7.6%, n=4). One experiment in the asenapine 1nM group was detected as an outlier according to the Grubbs test and therefore excluded.

![Concentration-response curves for both asenapine and escitalopram of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-induced response at (a) 5 and (b) 30 minutes after drug application. Each point represents the mean ± SEM percent of control (n=3--7). The holding potential was −60 mV.](ijnppy_pyu068_f0004){#F4}

![Effects on α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-induced currents in pyramidal cells of the rat medial prefrontal cortex (mPFC). Representative electrophysiological traces showing the effect of AMPA application before (grey trace) and after application (black trace) of 3nM escitalopram (a), 1nM asenapine (b), 3nM escitalopram + 1nM asenapine (c), and 3nM escitalopram + 1nM asenapine + 1 µM SCH23390 (d). The grey and black horizontal bars indicate time of AMPA application for control and test trace, respectively. Data is summarized in bar charts 5 (e) and 30 (f) minutes after drug application. The results are presented in percent as mean ± SEM. \**P*\<.05, \*\**P*\<.01 vs. control response. \#*P*\<.05, \#\#*P*\<.01, \#\#\#*P*\<.001 as indicated in figure (n=4--7). The holding potential was −60 mV.](ijnppy_pyu068_f0005){#F5}

Add-on Asenapine to Escitalopram Potentiates Electrically Evoked EPSPs in Pyramidal Cells of the Rat mPFC {#s14}
---------------------------------------------------------------------------------------------------------

Asenapine (1nM) treatment facilitated the electrically evoked EPSP and induced action potentials in 1 of 4 cells tested, whereas escitalopram (3nM) had no effect in any cell tested (for representative traces, see [Figure 6a](#F6){ref-type="fig"}-[b](#F6){ref-type="fig"}). However, the addition of asenapine (1nM) to escitalopram (3nM) facilitated the evoked EPSPs and induced bursts of action potentials overriding the EPSP in all 4 cells tested ([Figure 6c](#F6){ref-type="fig"}). The effect of the combination of asenapine and escitalopram gradually increased over time, and the time to onset of the first spike varied between cells from 5 to 35min.

![Effects of asenapine, escitalopram, and the combination of asenapine and escitalopram on electrically evoked excitatory postsynaptic potentials (EPSPs) in pyramidal cells of the rat medial prefrontal cortex (mPFC). Representative electrophysiological traces showing the EPSPs before (grey) and after (black) application of 3nM escitalopram (a), 1nM asenapine (b), and 3nM escitalopram + 1nM asenapine (c). Arrows indicate time of electrical stimulation. The logarithm of the mean EPSP area (log~10~ mV\*ms) is summarized in d. The results are presented as mean ± SEM (n=4). The combination of asenapine and escitalopram significantly enhanced the EPSP area compared with both escitalopram (\*\**P*\<.01, \*\*\* *P*\<.001) and asenapine (\#\#*P*\<.01) as well as its own control EPSP area (ie, the EPSP area before drug application; ¤¤¤ *P*\<.001).](ijnppy_pyu068_f0006){#F6}

The area of the evoked EPSP was quantified using Clampfit 9.2 with the baseline set manually. Due to the large variation of the EPSP area (expressed as mV\*ms), the data were log transformed before statistical analysis. There was no difference in the control EPSP area between the different groups, that is, the EPSP area assessed before drug treatment ([Figure 6d](#F6){ref-type="fig"}). However, the combination of asenapine and escitalopram significantly enhanced the EPSP area compared with both escitalopram- and asenapine-treated groups as well as compared with its own control response ([Figure 6d](#F6){ref-type="fig"}; 2-way repeated-measures ANOVA \[F~8,36~=3.14, *P*\<0.01\]; Fisher's Least Significant Difference test *P*\<0.01-.001).

Discussion {#s15}
==========

The present study demonstrates that low doses of the atypical APD asenapine in combination with escitalopram generate a marked enhancement of extracellular dopamine, noradrenaline, and serotonin outflow in the mPFC as well as increases dopamine outflow in NAc. Furthermore, the combination of low, clinically relevant concentrations of asenapine and escitalopram facilitated glutamatergic transmission in the rat mPFC. Interestingly, the observed effect on AMPAR-mediated transmission was not attainable by each drug given alone, even at higher concentrations, indicating that the two drugs work synergistically to generate this effect. The effects on both NMDAR- and AMPAR-mediated transmission were, at least in part, mediated via activation of the dopamine D1R, as the facilitatory effects of the drug combination on both NMDAR- and AMPAR-mediated transmission were antagonized by a D1R antagonist. Importantly, the combination of asenapine and escitalopram also facilitated electrically evoked EPSPs and induced bursts of action potentials in pyramidal cells, further supporting a physiologically relevant facilitation of prefrontal glutamatergic transmission.

Our results generally support the notion that the augmentation of the antidepressant effect of SSRIs by atypical APDs in treatment-resistant MDD may be related to enhanced catecholamine output in prefrontal cortical areas (c.f. Introduction). The enhanced prefrontal catecholamine outflow induced by addition of asenapine to escitalopram with ensuing activation of NMDAR-mediated transmission, following D1R activation, may be of clinical significance, since the degree of cognitive impairment is a critical determinant of treatment outcome in MDD and BPD as well as in schizophrenia (c.f. Introduction). Given that the addition of asenapine to escitalopram significantly facilitated NMDAR-mediated transmission via activation of D1R, the present results propose that add-on low doses of asenapine to SSRIs such as escitalopram may be used clinically to ameliorate certain aspects of cognitive impairment, since the D1R and NMDAR interaction is a mechanism highly implicated in cognitive functioning ([@CIT0009]). Moreover, recent clinical and preclinical studies have shown that drugs mediating their effect via the co-agonist site of the NMDAR may possess an antidepressant effect ([@CIT0031]; [@CIT0022]), indicating that in addition to an effect on cognition, activation of NMDARs may contribute to an antidepressant effect per se.

The effect of addition of asenapine to escitalopram on mono amine release was dose dependent, since addition of the lower dose of asenapine (0.05mg/kg) to escitalopram induced a synergistic increase in dopamine release, whereas the higher dose (0.1mg/kg) potentiated serotonin and noradrenaline output but did not further enhance dopamine output compared with asenapine given alone. The higher dose may block postsynaptic receptors to a higher extent than the lower dose and potentially reduce feed-back inhibition.

The mechanisms by which the addition of asenapine to escitalopram produced these effects on monoaminergic transmission may involve action on several receptors. Previous studies have shown that SSRI-induced serotonin release acting on 5-HT2Rs on GABAergic interneurons inhibits locus coeruleus cell firing activity, and simultaneous treatment with an SSRI and a 5-HT2AR antagonist enhances both serotonergic and noradrenergic neuronal activity ([@CIT0050] [@CIT0051]). Indeed, 5-HT2AR antagonists have been found to potentiate the antidepressant-like effect of an SSRI ([@CIT0034]).

Moreover, 5-HT2AR blockage appears to augment D2R antagonist-induced dopamine release via a 5-HT1AR-mediated mechanism ([@CIT0023]), and the 5-HT1AR agonist 8-OH-DPAT increases burst firing and firing rate of prefrontally projecting neurons in the ventral tegmental area as well as preferentially increase dopamine output in the mPFC ([@CIT0002] [@CIT0003]). A more recent study found that activation of postsynaptic 5-HT1ARs in the PFC enhanced dopamine cell firing in the ventral tegmental area and increased dopamine release in the same brain region ([@CIT0013]). It seems possible that at the higher dose of asenapine (0.1mg/kg), the postsynaptic stimulation of 5-HT1ARs in the PFC is governed by the intrinsic activity of asenapine at 5-HT1ARs, which may thus attenuate the stimulatory effect on dopamine cell firing of enhanced serotonin in the PFC induced by serotonin transporter blockade blockade and consequently attenuate dopamine release in the mPFC, which would contribute to explaining why dopamine release is not further enhanced by the higher dose of asenapine. Adjunctive treatment with an α~2~-adrenoceptor antagonist increases firing activity of noradrenergic neurons originating in the locus coeruleus following administration of antidepressant drugs ([@CIT0049]) and potentiates cortical monoamine release induced by SSRIs ([@CIT0019]). Previous studies show that adjunctive treatment with α~2~-adrenoceptor antagonists may potentiate the effect of antidepressant drugs and generate a more rapid onset of action ([@CIT0043]; [@CIT0012]; [@CIT0058]). Consequently, the antagonistic action of asenapine at α~2~-adrenoceptors, 5-HT2ARs and partial agonistic effect at 5-HT1ARs may all provide mechanisms contributing to an enhanced monoamine release and allow for substantial improvement of the efficacy of SSRIs. In addition, as dopamine release in NAc is involved in reward-related behaviors ([@CIT0014]), enhanced mesolimbic dopamine release induced by asenapine and escitalopram may contribute to ameliorate anhedonia in MDD.

In the present study, a combination of asenapine and escitalopram facilitated AMPA-induced currents in pyramidal cells of the mPFC. The observation that this drug combination, like ketamine and scopolamine, markedly facilitates glutamatergic transmission, particularly AMPAR-mediated transmission in the rat mPFC ([@CIT0030]; [@CIT0029]; [@CIT0057]), may thus contribute to explaining the rapid onset of the enhanced antidepressant effect obtained by adjunctive treatment with atypical APDs to SSRIs (c.f. Introduction).

Given the complex interaction between the monoaminergic systems and the glutamatergic system in the mPFC, where, for example, dopamine and serotonin can either increase or decrease glutamatergic transmission (for reviews, see, eg, [@CIT0041]; [@CIT0054]) and the complex pharmacology of the asenapine and escitalopram combination, the precise mechanisms by which the combination, but not either drug when given separately, facilitates AMPAR-mediated transmission remains to be fully understood. Previous electrophysiological studies did not reveal any effect of D1R activation on AMPAR-mediated transmission in the mPFC ([@CIT0045]; [@CIT0056]), whereas D2R activation seems to decrease AMPAR-mediated transmission ([@CIT0056]). In cell cultures, however, D1R activation has been found to increase the surface expression of AMPARs on prefrontal pyramidal cells, whereas D2R had the opposite effect, although D1R activation by itself may not be sufficient to induce translocation of AMPARs to synaptic sites ([@CIT0048]). Thus, the facilitating effect of the asenapine and escitalopram combination may, at least in part, be explained by increased dopamine output in the mPFC induced by the combination of asenapine and escitalopram in combination with a concomitant blockade of postsynaptic D2Rs by asenapine, resulting in a preferential activation of D1Rs enhancing the surface expression of AMPARs. However, it is likely that D1R activation is not the sole mechanism involved, since neither asenapine nor escitalopram facilitated AMPAR-mediated transmission when given alone, even at concentrations where these drugs have previously been found to increase NMDAR-mediated transmission via this mechanism ([@CIT0024], [@CIT0044]). Taken together, we propose that D1R activation by asenapine and escitalopram may well be necessary, but probably not entirely sufficient, to facilitate AMPAR-mediated transmission. In addition to the effects of D1R activation, serotonin has been found to induce glutamate release ([@CIT0001]). Moreover, serotonin may activate postsynaptically located 5-HT1ARs ([@CIT0007]) or 5-HT1B receptors ([@CIT0008]) which may contribute to modulate AMPAR-mediated transmission, thus suggesting that the enhanced AMPAR-mediated transmission may well be mediated by a combination of these mechanisms. The facilitatory effect of the combination of asenapine and escitalopram on the EPSPs is in analogy with the corresponding effect previously observed with the clozapine, which was found to be both NMDAR- and D1R-mediated ([@CIT0010]). The latency to the onset of the spikes varied, indicating that the bursts of action potentials may be the result of polysynaptic input from lateral interconnected pyramidal cells ([@CIT0010]). This polysynaptic input could also contribute to the increased EPSP area by inducing several EPSPs with different latencies, superimposed on the initial EPSP. Clinically, the increased pyramidal cell excitability in the mPFC may thus probably serve to ameliorate both cognitive and depressive symptoms.

In conclusion, our results demonstrate that a low dose of asenapine in combination with escitalopram can produce a marked activation of prefrontal monoamine output with an ensuing facilitation of glutamatergic transmission in the mPFC, neurobiological effects that may generate both a procognitive effect and an enhanced antidepressant activity in mood disorders such as MDD and BPD as well as schizophrenia. Our data also suggest that activation of the dopamine D1R may be crucial for this effect. Importantly, the results propose that adding asenapine to SSRIs such as escitalopram may produce a faster onset of action of the antidepressant effect compared with an SSRI alone, a low risk of conversion to mania in BPD, and probably with only modest weight gain and low EPS liability in mood disorders.
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